Aditxt Inc (NASDAQ:ADTX) rose Tuesday. Aditxt recently announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic.
The announcement, handed down in mid-July, revealed A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individual’s immune response to the SARS-CoV-2 virus.
"Everyone’s immune response is unique to that individual. We have been studying individual immune responses to COVID-19 and COVID-19 vaccination, and we are finding that the immediacy, strength, and duration of antibody responses can vary widely based on a multitude of variables," said CEO Amro Albanna.
"We believe that as more people become vaccinated or exposed to the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics adds that next level of precision, delivering more detailed information of the strength of immune response against the virus."
AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual’s immune response to multiple antigens associated with the SARS-CoV-2 virus. This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individual’s immune response in a single test cycle.
With this new enhancement, AditxtScore for COVID-19 now includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.
ADTX shares moved higher eight cents, or 3.4%, to $2.43.
